Back to Directory
Difelikefalin
Performance & EnduranceKappa opioid receptor agonist for uremic itch in dialysis patients.
Key Benefits
- ✓Treats uremic itch
- ✓Reduces pruritus in dialysis
- ✓No CNS opioid effects
- ✓Improves quality of life
- ✓Selective peripheral action
Dosing Information
Dosage Range
0.5 mcg/kg
Frequency
Three times weekly during dialysis
Typical Duration
Ongoing
Detailed Protocol
Administered intravenously during each hemodialysis session. Given as bolus injection three times weekly during dialysis. Prescription only for dialysis patients.
About Difelikefalin
Difelikefalin (Korsuva) is a synthetic tetrapeptide that selectively activates peripheral kappa opioid receptors without CNS effects. FDA-approved for moderate-to-severe pruritus (itch) in hemodialysis patients.
Research Notes
FDA-approved in 2021 for uremic pruritus. Unique mechanism targeting peripheral kappa receptors. Significant improvement in itch for dialysis patients.
Potential Side Effects
- •Diarrhea
- •Dizziness
- •Vomiting
- •Generally well tolerated
- •No addiction potential
Always consult with a healthcare professional before starting any peptide therapy.